Search Results

By The ASCO Post Staff  / Friday, June 7, 2013 12:22 PM

ASCO 2013: Novel Heat Shock Protein Inhibitor Effective in Combination with Docetaxel as Second-line Therapy for Advanced Lung Cancer

A large randomized phase II study, GALAXY-1, found that a novel heat shock protein (Hsp) 90 inhibitor, ganetespib, when combined with docetaxel in second-line therapy, leads to longer overall survival compared to standard second-line docetaxel alone in patients with advanced lung adenocarcinoma...